|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese Stroke Center Alliance:a national effort to improve healthcare quality for acute stroke and transient ischaemic attack:rationale,design and preliminary findings显示文摘Background In June 2015,the Chinese Stroke Association(CSA)initiated the Chinese Stroke Center Alliance(CSCA)to establish the national hospital-based stroke care quality assessment and improvement platform.This article outlines its objectives,operational structure,patient population,quality improvement(QI)intervention tools,data elements,data collection methodology and current patient and hospital data.Methods The CSCA is a national,hospital-based,multicentre,voluntary,multifaceted intervention and continuous QI initiative.This multifaceted intervention includes stroke centre development,written care protocols,workshops and a monitoring/feedback system of evidencebased performance measures.The data coordinating centre of the CSCA resides at the China National Clinical Research Center for Neurological Diseases,Beijing Tiantan Hospital.results As of July 2017,1576 hospitals in China have contributed detailed clinical information to serve as a benchmark for the stroke care quality of 433264 patients with acute stroke/transient ischaemic attacks(TIA),including 352572(81.38%)acute ischaemic stroke,30362(7.01%)TIA,42080(9.71%)spontaneous intracranial haemorrhage,5505(1.27%)subarachnoid haemorrhage and 2745(0.63%)not specified stroke.Conclusion The CSCA programme is designed to establish a continuous national stroke registry and help healthcare providers develop stroke centres and treat patients in a consistent manner in accordance with accepted national guidelines and,ultimately,improve patient outcomes.It supports the CSA mission to reduce stroke burden in China. | Yongjun Wang Zixiao Li Yilong Wang Xingquan Zhao Liping Liu Xin Yang Caiyun Wang Hongqiu Gu Fuying Zhang Chunjuan Wang Ying Xian David Z Wang Qiang Dong Anding Xu Jizong Zhao Chinese Stroke Center Alliance investigators | 2018 | Stroke & Vascular Neurology2018，3，4： | 38 |
| 2 | Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial显示文摘Methods:IMpower010 was a randomised,multicentre,open-label,phase 3 study done at 227 sites in 22 countries and regions.Eligible patients were 18 years or older with completely resected stage IB(tumours>4 cm)to IIIA NSCLC per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system(7th edition).Patients were randomly assigned(1:1)by a permuted-block method(block size of four)to receive adjuvant atezolizumab(1200 mg every 21 days;for 16 cycles or 1 year)or best supportive care(observation and regular scans for disease recurrence)after adjuvant platinum-based chemotherapy(one to four cycles).The primary endpoint,investigator-assessed disease-free survival,was tested hierarchically first in the stage II-IIIA population subgroup whose tumours expressed PD-L1 on 1%or more of tumour cells(SP263),then all patients in the stage II-IIIA population,and finally the intention-to-treat(ITT)population(stage IB-IIIA).Safety was evaluated in all patients who were randomly assigned and received atezolizumab or best supportive care.IMpower010 is registered with ClinicalTrials.gov,NCT02486718(active,not recruiting). | Enriqueta Felip | 2021 | 四川生理科学杂志2021，43，8： | 21 |
| 3 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial显示文摘Background:We aimed to assess efficacy and safety,with a special focus on cardiovascular safety,of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications.Methods:This open-label,parallel-group,phase 3 study was done in 187 sites in 14 countries on five continents.Eligible participants,aged 18 years or older,had type 2 diabetes treated with any combination of metformin,sulfonylurea,or sodiumglucose co-transporter-2 inhibitor,a baseline glycated haemoglobin(HbA1c)of 7-5-10-5%(58-91 mmol/mol),body-mass index of 25 kg/m2 or greater,and established cardiovascular disease or a high risk of cardiovascular events.Participants were randomly assigned(1:1:1:3)via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide(5 mg,10 mg,or 15 mg)or glargine(100 U/mL),titrated to reach fasting blood glucose of less than 100 mg/dL.The primary endpoint was non-inferiority(0-3%non-inferiority boundary)of tirzepatide 10 mg or 15 mg,or both,versus glargine in HbA1c change from baseline to 52 weeks.All participants were treated for at least 52 weeks,with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events(MACE).Safety measures were assessed over the full study period.This study was registered with ClinicalTrials.gov,NCT03730662. | Stefano Del Prato | 2021 | 四川生理科学杂志2021，43，8： | 16 |
| 4 | WRF、EC和T639模式在福建沿海冬半年大风预报中的检验与应用显示文摘基于福建省冬半年沿海和港湾岛屿自动站的逐时极大风观测资料和WRF(Weather Research and Forecast)、EC(European Centre for Medium-Range Weather Forecasts)细网格以及T639(TL639L60)三种模式预报的10 m风场资料,将模式预报的风向风速与观测资料进行对比检验,结果表明:福建省沿海冬半年大风的盛行风向以东北风为主,大风的时空分布极为不均,沿海风力的脉动性、跳跃性、局地性突出。从三种模式对风速风向的模拟效果来看, WRF和EC细网格的预报效果较好,有可参考性, T639可参考性不高。对于风速,模式预报结果相比实况极大风速偏小,港湾岛屿代表站风速的平均绝对误差均小于沿海代表站,预报平均误差由沿海向内陆逐渐减小,由中部向南北逐渐减小。风向相比风速的预报效果要差, WRF和EC细网格的风向预报误差在45°-50°,有一定的参考意义;港湾岛屿代表站风向的平均绝对误差大于沿海代表站,以浮标站的误差最大。当观测风速出现7级及以上风速时,若对大风进行分级检验,则较低风速的预报平均绝对误差小于较高风速;风向预报的平均绝对误差也大大降低,且误差都在45°以内,具有良好的参考性。 | 曾瑾瑜 韩美 吴幸毓 林青 廖廓 | 2015 | 海洋科学2015，39，7： | 15 |
| 5 | 加拿大多伦多Sunnybrook Health Sciences Centre NICU护理对我国的借鉴显示文摘通过介绍Sunnybrook Health Sciences Centre NICU的护理管理和工作制度、医院感染预防、病房布局、护理业务培训和对早产儿发育的护理等内容,为我国NICU护理工作开展提供借鉴。提出我国应该加强根据国内外的最新护理进展情况规范NICU护士专科知识教材和培训方法;合理布局NICU,以改善病房环境和预防医院感染;合理安排治疗和护理时间,尽量减少对早产儿的干扰,促进其发育;鼓励父母参与患儿的护理。 | 申叶林 黄碟卿 | 2008 | 护理学报2008，15，2： | 13 |
| 6 | A Two-step Estimation Method of Troposphere Delay with Consideration of Mapping Function Errors显示文摘Mapping function errors are usually not taken into consideration, when space geodetic data observed by VLBI, GNSS and some other techniques are utilized to estimate troposphere delay, which could, however, probably bring non-ignorable errors to solutions. After analyzing the variation of mapping function errors with elevation angles based on several-year meteorological data, this paper constructed a model of this error and then proposed a two-step estimation method of troposphere delay with consideration of mapping function errors. The experimental results indicate that the method put forward by this paper could reduce the slant path delay residuals efficiently and improve the estimation accuracy of wet tropospheric delay to some extent. | Haopeng FAN Zhongmiao SUN Liping ZHANG Xiaogang LIU | 2020 | Journal of Geodesy and Geoinformation Science2020，3，1： | 11 |
| 7 | Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study显示文摘Background Tenecteplase(TNK)possesses several pharmacological characteristics superior to conventional alteplase(rt-PA),with well-established safety and efficacy profile in Caucasians.There exists controversy over the optimal dose of intravenous rt-PA for East Asians with acute ischaemic stroke(AIS).Current study aimed to determine the safety dose range of recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)for patients with AIS in China.Methods This multicentre,prospective,randomised,open-label,blinded end-point,phase II study compared three tiers of 0.1,0.25,0.32 mg/kg rhTNK-tPA(to a maximum of 40 mg)with standard 0.9 mg/kg rt-PA(to a maximum of 90 mg)in patients who were eligible for intravenous thrombolysis.The safety outcome were symptomatic intracranial haemorrhage(sICH)within 36 hours.Results Between May 2018 and February 2020,240 patients were randomly assigned to four group,4 of whom did not receive study treatment.The intention-to-treat analysis included 236 patients.There was no difference in the improvement on National Institutes of Health Stroke Scale at day 14 in the 3 tiers and control group(63.3%,77.2%,66.7%vs 62.7%).The number of sICH was 3 of 60(5.0%)in the 0.1 mg/kg group,none in the 0.25 mg/kg group,2 of 60(3.3%)in the 0.32 mg/kg group and 1(1.7%)of 59 in the rt-PA group.There were no significant between-group differences in severe adverse events.Conclusions Similar to the Caucasians,rhTNK-tPA was well tolerated in Chinese patients with AIS at all doses administered within 3 hours of symptom onset.The dose-efficacy profile of rhTNK-tPA needs to be established with future investigations. | Shuya Li Yuesong Pan Ziran Wang Zhigang Liang Huisheng Chen Dong Wang Yi Sui Xingquan Zhao Yilong Wang WanLiang Du Huaguang Zheng Yongjun Wang | 2022 | Stroke & Vascular Neurology2022，7，1： | 9 |
| 8 | Endovascular therapy for Acute ischemic Stroke Trial (EAST): study protocol for a prospective, multicentre control trial in China显示文摘Background and purpose:5 recent trials have shown the benefit of endovascular treatment for acute ischaemic stroke(AIS)due to large vessel occlusion of the anterior circulation.This study aims to evaluate the safety and efficacy of Solitaire thrombectomy in patients with moderate-to-severe stroke in the Chinese population,which has a high prevalence of intracranial atherosclerosis.Methods and analysis:This multicentre prospective control study will involve 17 stroke centres in China,and plans to recruit 150 patients in the intervention group,and 150 patients in the medical group,in which patients meet enrolment criteria but refuse intervention.Patients with AIS due to large vessel occlusion indicated for treatment with Solitaire stent retriever within 12 hours of symptom onset,and who meet the inclusion and exclusion criteria,will be enrolled in this study.The primary efficacy endpoint is functional independence as defined by a modified Rankin Scale(mRS)score≤2 at 90 days or by functional improvement as defined by mRS,using shift analysis.The procedural efficacy endpoint is arterial recanalisation of the occluded target vessel measured by a modified Thrombolysis in Cerebral Infarction(mTICI)score equal or superior to 2b right following the use of the study device.The primary safety endpoint is symptomatic intracranial haemorrhage(sICH)within 24±3 hours postprocedure.Ethics and dissemination:The protocol was approved by the Ethics Committee at the coordinating centre and by the local Institutional Review Board of each participating centre.Trial registration number:NCT02350283. | Zhongrong Miao Xiaochuan Huo Feng Gao Xiaoling Liao Chunjuan Wang Ya Peng Yibin Cao Shengli Chen Meng Zhang Changchun Jiang Xiaoxiang Peng Cunfeng Song Liping Wei Qiyi Zhu Zaiyu Guo Li Liu Hang Lin Hua Yang Wei Wu Hui Liang Anding Xu Kangning Chen Xingquan Zhao Yuesong Pan Hao Li Liping Liu Yilong Wang Yongjun Wang EAST investigators | 2016 | Stroke & Vascular Neurology2016，1，2： | 8 |
| 9 | Biomarkers in the clinical management of patients with atrial fibrillation and heart failure显示文摘Atrial fibrillation(AF)and heart failure(HF)are two cardiovascular diseases with an increasing prevalence worldwide.These conditions share common pathophysiologiesand frequently co-exit.In fact,the occurrence of either condition can‘cause’the development of the other,creating a new patient group that demands different management strategies to that if they occur in isolation.Regardless of the temproral association of the two conditions,their presence is linked with adverse cardi-ovascular outcomes,increased rate of hospitalizations,and increased economic burden on healthcare systems.The use of low-cost,easily accessible and applicable biomarkers may hasten the correct diagnosis and the effective treatment of AF and HF.Both AF and HF effect multiple physiological pathways and thus a great number of biomarkers can be measured that potentially give the clinician important diagnostic and prognostic information.These will then guide patient centred therapeutic management.The current biomarkers that offer potential for guiding therapy,focus on the physiological pathways of miRNA,myocardial stretch and injury,oxidative stress,inflammation,fibrosis,coagulation and renal impairment.Each of these has different utility in current clinincal practice. | Ioanna Koniari Eleni Artopoulou Dimitrios Velissaris Mark Ainslie Virginia Mplani Georgia Karavasili Nicholas Kounis Grigorios Tsigkas | 2021 | Journal of Geriatric Cardiology2021，18，11： | 8 |
| 10 | Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders:executive summary and 2019 update on organizational stroke management显示文摘Aim Stroke is characterised by high morbidity,mortality and disability,which seriously affects the health and safety of the people.Stroke has become a serious public health problem in China.Organisational stroke management can significantly reduce the mortality and disability rates of patients with stroke.We provide this evidence-based guideline to present current and comprehensive recommendations for organisational stroke management.Methods A formal literature search of MEDLINE(1 January 1997 through 30 September 2019)was performed.Data were synthesised with the use of evidence tables.Writing group members met by teleconference to discuss data-derived recommendations.The Chinese Stroke Association’s Levels of Evidence grading algorithm was used to grade each recommendation.results Evidence-based guidelines are presented for the organisational management of patients presenting with stroke.The focus of the guideline was subdivided into prehospital first aid system of stroke,rapid diagnosis and treatment of emergency in stroke centre,organisational management of stroke unit and stroke clinic,construction of regional collaborative network among stroke centres and evaluation and continuous improvement of stroke medical quality.Conclusions The guidelines offer an organisational stroke management model for patients with stroke which might help dramatically. | Min Lou Jing Ding Bo Hu Yusheng Zhang Hao Li ZeFeng Tan Yan Wan An-Ding Xu Chinese Stroke Association Stroke Council Guideline Writing Committee | 2020 | Stroke & Vascular Neurology2020，5，3： | 7 |
| 11 | Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease:a multicentre,randomised,double-blind,parallel-group,phase 3b trial显示文摘Background:Active-comparator trials are important to inform patient and physician choice.We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease. | Bruce E Sands | 2022 | 四川生理科学杂志2022，44，5： | 6 |
| 12 | Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke:the first multicentre,phase III trial in China显示文摘background and purpose Data on the efficacy and safety of alteplase for acute ischaemic stroke(AIS)administered 3-4.5 hours after the onset of stroke symptoms in Chinese patients is limited.We sought to determine whether AIS patients would benefit from thrombolysis with alteplase between 3 and 4.5 hours after the onset of stroke symptoms in a prospective,multicentre,single-arm trial in China.Materials and methods Eligible AIS patients were given 0.9 mg/kg alteplase intravenously.The primary efficacy endpoint was a favourable outcome at 3 months,defined as a score of 0 or 1 on the modified Rankin Scale.Thresholds for the primary efficacy endpoint were determined to be 40%based on the literature review.The primary safety endpoint was symptomatic intracranial haemorrhage(sICH)according to the European Cooperative Acute Stroke Study III(ECASS III)trial definition.Post hoc analysis between this study and the ECASS III trial were compared using the propensity score matching(PSM)method.results A total of 120 eligible AIS patients from 11 sites in China received thrombolysis therapy in this study.The median time from onset of symptoms to needle was 3 hours 54 min.The percentage of patients with a favourable outcome was 63.3%(95%CI 54.4 to 71.4),significantly higher than the predefined threshold(p<0.0001).Three patients(2.5%,95%CI 0.5 to 7.1)had sICH,including two fatal sICH.Six patients died within 3 months after treatment.The post hoc PSM analysis showed a numerically higher rate of the primary efficacy endpoint in this study(63.3%)than the matched placebo arm(56.7%)in the ECASS III trial.Conclusions Intravenous alteplase with a standard dose administered between 3 and 4.5 hours after onset of symptoms is effective and safe for Chinese AIS patients. | Huaguang Zheng Yi Yang Huisheng Chen Chuanling Li Yangkun Chen Fu-Dong Shi Li Yang Xiaoping Cui Zuneng Lu Yanling Liang Songbiao Cui Anding Xu Yiqing Wu Yaqing Sun Yongjun Wang | 2020 | Stroke & Vascular Neurology2020，5，3： | 4 |
| 13 | Fold-Hopf bifurcation in a simplified four-neuron BAM (bidirectional associative memory) neural network with two delays显示文摘The bidirectional associative memory (BAM) neural network with four neurons and two delays is considered in the present paper.A linear stability analysis for the trivial equilibrium is firstly employed to provide a possible critical point at which a zero and a pair of pure imaginary eigenvalues occur in the corresponding characteristic equation.A fold-Hopf bifurcation is proved to happen at this critical point by the nonlinear analysis.The coupling strength and the delay are considered as bifurcation parameters to investigate the dynamical behaviors derived from the fold-Hopf bifurcation.Various dynamical behaviours are qualitatively classified in the neighbourhood of the fold-Hopf bifurcation point by using the center manifold reduction (CMR) together with the normal form.The bifurcating periodic solutions are expressed analytically in an approximate form.The validity of the results is shown by their consistency with the numerical simulation. | GE JuHong & XU Jian School of Aerospace Engineering and Applied Mechanics,Tongji University,Shanghai 200092,China | 2010 | Science China(Technological Sciences)2010，53，3： | 3 |
| 14 | Integrated Assessment of Natural Hazards, Including Climate Change’s Influences, for Cultural Heritage Sites: The Case of the Historic Centre of Rethymno in Greece显示文摘Within the framework of disaster risk management, this article proposes an interdisciplinary method for the analysis of multiple natural hazards, including climate change’s influences, in the context of cultural heritage. A taxonomy of natural hazards applicable to cultural heritage was developed based on the existing theoretical and conceptual frameworks. Sudden-onset hazards, such as earthquakes and floods, and slow-onset hazards, such as wetting–drying cycles and biological contamination, were incorporated into the hazard assessment procedure. Future alteration of conditions due to climate change, such as change in heat waves’ duration, was also taken into account. The proposed hazard assessment framework was applied to the case of the Historic Centre of Rethymno, a city on the northern coast of the island of Crete in Greece,to identify, analyze, and prioritize the hazards that have the potential to cause damage to the center’s historic structures. The assessment procedure includes climate model projections, GIS spatial modeling and mapping, and finally a hazard analysis matrix to enable the sharing of a better understanding of multiple hazards with the stakeholders.The results can facilitate decision making by providing the vulnerability and risk analysis with the nature and spatial distribution of the significant hazards within the study area and its setting. | Mohammad Ravankhah Rosmarie de Wit Athanasios V.Argyriou Angelos Chliaoutakis Maria Joao Revez Joern Birkmann Maja Zuvela-Aloise Apostolos Sarris Anastasia Tzigounaki Kostas Giapitsoglou | 2019 | International Journal of Disaster Risk Science2019，10，3： | 3 |
| 15 | Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo- controlled trial显示文摘Background Studies show tranexamic acid can reduce the risk of death and early neurological deterioration after intracranial haemorrhage.We aimed to assess whether tranexamic acid reduces haematoma expansion and improves outcome in intracerebral haemorrhage patients susceptible to haemorrhage expansion.Methods We did a prospective,double-blind,randomised,placebo-controlled trial at 10 stroke centres in China.Acute supratentorial intracerebral haemorrhage patients were eligible if they had indication of haemorrhage expansion on admission imaging(eg,spot sign,black hole sign or blend sign),and were treatable within 8 hours of symptom onset.Patients were randomly assigned(1:1)to receive either tranexamic acid or a matching placebo.The primary outcome was intracerebral haematoma growth(>33% relative or>6 mL absolute)at 24 hours.Clinical outcomes were assessed at 90 days.Results Of the 171 included patients,124(72.5%)were male,and the mean age was 55.9±11.6 years.89 patients received tranexamic acid and 82 received placebo.The primary outcome did not differ significantly between the groups:36(40.4%)patients in the tranexamic acid group and 34(41.5%)patients in the placebo group had intracranial haemorrhage growth(OR 0.96,95% CI 0.52 to 1.77,p=0.89).The proportion of death was lower in the tranexamic acid treatment group than placebo group(8.1%vs 10.0%),but there were no significant differences in secondary outcomes including absolute intracranial haemorrhage growth,death and dependency.Conclusions Among patients susceptible to haemorrhage expansion treated within 8 hours of stroke onset,tranexamic acid did not significantly prevent intracerebral haemorrhage growth.Larger studies are needed to assess safety and efficacy of tranexamic acid in intracerebral haemorrhage patients. | Jingyi Liu Ximing Nie Hongqiu Gu Qi Zhou Haixin Sun Ying Tan Dacheng Liu Lina Zheng Jiahui Zhao Yan Wang Yibin Cao Haomeng Zhu Yunpeng Zhang Lijin Yi Yuehua Pu Miao Wen Zhonghua Yang Shengjun Sun Wenzhi Wang Xingquan Zhao Liping Liu Yongjun Wang | 2021 | Stroke & Vascular Neurology2021，6，2： | 3 |
| 16 | Lessons learned from study of congenital hip disease in adults显示文摘Orthopaedic surgeons specialising in adult hip reconstruction surgery often face the problem of osteoarthritis secondary to congenital hip disease(CHD). To achieve better communication among physicians,better treatment planning and evaluation of the results of various treatment options,an agreed terminology is needed to describe the entire pathology. Furthermore,a generally accepted classification of the deformities is necessary. Herein,the authors propose the use of the term 'congenital hip disease' and its classification as dysplasia,low dislocation and high dislocation. Knowledge of the CHD natural history facilitates comprehension of the potential development and progression of the disease,which differs among the aforementioned types. This can lead to better understanding of the anatomical abnormalities found in the different CHD types and thus facilitate preoperative planning and choice of the most appropriate management for adult patients. The basic principles for improved results of total hip replacement in patients with CHD,especially those with low and high dislocation,are: Wide exposure,restoration of the normal centre of rotation and the use of special techniques and implants for the reconstruction of the acetabulum and femur. Application of these principles during total hip replacement in young female patients born with severe deformities of the hip joint has led to radical improvement of their quality of life. | George Hartofilakidis Kalliopi Lampropoulou-Adamidou | 2016 | World Journal of Orthopedics2016，7，12： | 3 |
| 17 | Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke(ATAMIS):a parallel,randomised,open-label,multicentre,prospective study显示文摘Background A recent study shows that dual antiplatelet therapy with clopidogrel plus aspirin is superior to aspirin monotherapy for minor stroke,which is defined as a National Institutes of Health Stroke Scale(NIHSS)score of≤3.However,acute mild-moderate ischaemic stroke(4≤NIHSS≤10)still needs aggressive antiplatelet intervention to prevent deterioration and recurrence of stroke.The efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy in the population are not clear.A multicentre clinical trial is designed to evaluate the efficacy and safety of clopidogrel plus aspirin therapy versus aspirin monotherapy within 48 hours of symptom onset of mild-moderate ischaemic stroke.Methods/Design The study is a randomised,open-label,multicentre,prospective trial with a target enrolment of 2700 patients from 60 centres in Northeast China.A treatment allocation identification number to each enrolled patient will be provided by a random number generator.The follow-up time for the clopidogrel plus aspirin and aspirin monotherapy groups is 90 days.The primary efficacy endpoint is a stroke progression event,which is defined as≥4 point increase in the NIHSS score in 48 hours.The second efficacy endpoints include new ischaemic stroke within 90 days,change in the NIHSS score within 14 days,modified Rankin Scale score on day 90 and other vascular or death events within 90 days.The safety endpoints include mucocutaneous haemorrhage,organ haemorrhage and intracranial haemorrhage,adverse events and severe adverse events.χ^(2)test,t-test(or Mann-Whitney test),survival analysis and Cox proportional hazards models will be conducted.The findings of the study may provide an important evidence for clinical practice for these patients.Discussion The trial will be conducted under a rational design and will provide valuable evidence on the appropriate treatment for this population.Ethics and dissemination The study was reviewed and approved by the Ethics Committee of the General Hospital of Shen-Yang Military Region(no K(2016)6).Trial registration number NCT02869009;Pre-results. | Xiaowen Hou Xiaoqiu Li Xinhong Wang Huisheng Chen | 2018 | Stroke & Vascular Neurology2018，3，4： | 3 |
| 18 | Clinical characteristics and in-hospital outcomes of patients receiving contemporary intensive cardiac care:retrospective study from a large centre in China显示文摘BACKGROUND Few studies from developed countries have quantitatively characterized the clinical characteristics and outcomes of patients receiving contemporary intensive cardiac care.We sought to investigate these data in patients admitted to a Chinese intensive cardiac care unit(ICCU).METHODS We conducted a retrospective study using data from 2,337 consecutive admissions to the ICCU at a large centre in China from June 2016 to May 2017.Data were captured after systematic inspection of individual medical records regarding current demographics,primary diagnosis,comorbidities,illnesses severity,and in-hospital outcomes.RESULTS The mean age was 65.6±14.2 years,and females accounted for 32.0%of patients.The Charlson Comorbidity Index and Oxford Acute Severity of Illness Score were 2.4±1.8 and 22.5±10.4,respectively.The top reason for admission was ST-segment elevation myocardial infarction(32.0%),and nonischaemic heart diseases accounted for 31.2%of all primary diagnoses.Noncardiovascular diseases were prevalent in the ICCU population,including chronic illnesses and acute noncardiovascular critical illnesses(ANCIs);in particular,21.7%of patients were marked by acute respiratory failure(14.6%),acute kidney injury(13.7%),sepsis(4.2%),or gastrointestinal bleeding(3.3%).The median length of stay in the ICCU and hospital were 1.1 days[interquartile range(IQR):0.8–2.6 days]and 6.3 days(IQR:3.8−10.9 days),respectively.The overall incidence of in-hospital death or discharge against medical advice under extremely critical conditions was 7.6%(n=177).Multivariate logistic regression analysis showed that the complexity of chronic illnesses and incident ANCIs were strong independent determinants for in-hospital outcomes.CONCLUSIONS Remarkable patient diversity and breadth of critical illnesses were observed in a Chinese ICCU population.Particularly,noncardiovascular diseases were prevalent and associated with adverse outcomes.Reformation of organization and staffing practices may be considered to adapt to the changed landscape. | Fei CHEN Yi-Ming LI Qi LIU Bao-Tao HUANG Fang-Yang HUANG Yong PENG Mao CHEN | 2021 | Journal of Geriatric Cardiology2021，18，2： | 2 |
| 19 | Multi-optimizationofasphericalmechanismforminimallyinvasivesurgery显示文摘In order to obtain the remote center motion(RCM) mechanism with better performance indexes and avoid the collision of multi-manipulators in minimally invasive surgery(MIS), a novel multi-objective optimization model was presented. There were two optimization objectives: a global kinematic performance index and a comprehensive stiffness index. Other indexes to characterize the design requirements such as collision probability, workspace, mechanism parameter, mass, and wall thickness were considered as constraints. Angles between two adjacent joints and cross-section dimensions of links were chosen as the design variables. The non-dominated sorting genetic algorithm II(NSGA-II) was adopted to solve the complex multi-objective optimization problem. Then, a 3-degree of freedom(DoF) MIS robotic prototype based on optimization results has been built up. The experiments to test the spatial position change of the remote center point and to test the absolute position accuracy and repetitive position accuracy of the MIS robot were achieved, and the experimental results meet the requirements of MIS. | 牛国君 潘博 张福海 封海波 付宜利 | 2017 | Journal of Central South University2017，24，6： | 2 |
| 20 | Acute Ischaemic Stroke Cooperation Group of Endovascular Treatment (ANGEL) registry: study protocol for a prospective, multicentre registry in China显示文摘Background and purpose Endovascular treatment could improve functional outcomes and reduce mortality in patients with intracranial large artery occlusion. This registry aims to evaluate the endovascular treatment delivery and to improve endovascular treatment algorithm in clinical practice for patients with stroke in China. Methods and analysis This multicentric, nationwide, prospective registry plans to include 20 stroke centres and recruit 900 consecutive AIS patients with large- artery occlusion under endovascular treatment. This registry will enrol acute large vessel occlusion patients suitable for endovascular treatment and the inclusion and exclusion criteria. In this study, 90 days functional independence (modified Rankin Scale score ≤2) is the primary efficacy endpoint. The procedural efficacy endpoint of this registry is target artery recanalisation defined by modified Thrombolysis in Cerebral Infarction score 2b or 3 after endovascular therapy. Symptomatic intracranial haemorrhage with 24±3 hours after the procedure is the primary safety endpoint of this registry. Ethics and dissemination Beijing Tiantan Hospital’s Ethics committee and all other participating centres approved the protocol and data collection of Acute Ischaemic Stroke Cooperation Group of Endovascular Treatment registry. Each participant or representative had a written informed consent. | Xiaochuan Huo Ning Ma Dapeng Mo Feng Gao Ming Yang Yilong Wang Yongjun Wang Zhongrong Miao ANGEL investigators | 2019 | Stroke & Vascular Neurology2019，4，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员